ERBB2 and ductal breast carcinoma in situ: Among the patients with intraductal carcinoma, seven (10.25%) exhibited triple positivity for hormonal receptors, nine patients (23.07%) were triple negative, 20 (51.28%) were ER/PR positive and HER2 negative, whereas three (7.7%) of the ductal carcinoma patients were HER2 positive and ER/PR negative.